Search bioRxiv⌕ Search

Biology subjects

Gil-Jimenez, A.

Publications and source records attributed to Gil-Jimenez, A..

2 recordsLinked to original sources

Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) currently achieve remarkable clinical results in urothelial cancer (UC). However, the relationship between the tumor microenvironment (TME), usually characterized by immune cell density, and response to ICI is unclear. We quantified the TME immune cell densities and spatial relationships (SRs) using the multiplex immunofluorescence data of 24 UC pre-treatment tumor resections. We described SRs by approximating the 1-NN distance distribution with a Weibull distribution and evaluated the association between TME metrics (spatial and density parameters) and ipilimumab+nivolumab response. Immune cell density did not discriminate between response groups. However, the Weibull SR metrics of CD8+ T-cells or macrophages to their closest cancer cell were positively associated with response. CD8+ T-cells close to B-cells were characteristic of non-response. The G- function, a threshold dependent alternative SR metric, yielded variable effect sizes and statistical power in association studies with response. We validated our SR response associations in a cohort of head and neck tumors with a comparable treatment design. Our data confirm that SRs, in contrast to density metrics, are strong biomarkers of response to ICIs, a finding with significant translational relevance.

cancer biology↗

T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancer

Immune checkpoint inhibitors (ICIs) improve overall survival in patients with metastatic urothelial cancer (mUC). To identify predictive markers of response, whole-genome DNA (n=70) and RNA-sequencing (n=41) were performed using fresh metastatic biopsies prior to treatment with pembrolizumab. PD-L1 combined positivity score did not, whereas tumor mutational burden and APOBEC mutagenesis modestly predicted response. Using gene expression analysis, we defined the T cell-to-stroma enrichment (TSE) score, a signature-based metric that captures the relative abundance of T cells and stromal cells. Patients with a positive and negative TSE score show progression-free survival rates at 6 months of 67 and 0%, respectively. The TSE score was captured by immunofluorescence in tumor tissue, and validated in two independent ICI-treated cohorts of patients with mUC (IMvigor210) and muscle-invasive UC (ABACUS). In conclusion, the TSE score represents a clinically applicable marker that potentially aids in prospectively selecting patients with mUC for ICI treatment.

cancer biology↗